These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 32859741)
21. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250 [TBL] [Abstract][Full Text] [Related]
22. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Chang SC; Lin JK; Yang SH; Wang HS; Li AF; Chi CW Int J Cancer; 2006 Apr; 118(7):1721-7. PubMed ID: 16231316 [TBL] [Abstract][Full Text] [Related]
23. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Puccini A; Lenz HJ; Marshall JL; Arguello D; Raghavan D; Korn WM; Weinberg BA; Poorman K; Heeke AL; Philip PA; Shields AF; Goldberg RM; Salem ME Oncologist; 2019 Mar; 24(3):319-326. PubMed ID: 30018131 [TBL] [Abstract][Full Text] [Related]
24. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East. Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205 [TBL] [Abstract][Full Text] [Related]
25. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain. Huang F; Tanaka H; Knudsen BS; Rutgers JK BMC Med Genet; 2020 Aug; 21(1):167. PubMed ID: 32838755 [TBL] [Abstract][Full Text] [Related]
26. Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. Kawai T; Nyuya A; Mori Y; Tanaka T; Tanioka H; Yasui K; Toshima T; Taniguchi F; Shigeyasu K; Umeda Y; Fujiwara T; Okawaki M; Yamaguchi Y; Goel A; Nagasaka T Clin Epigenetics; 2021 May; 13(1):117. PubMed ID: 34034807 [TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464 [TBL] [Abstract][Full Text] [Related]
28. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503 [TBL] [Abstract][Full Text] [Related]
30. Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability. Li L; Zhou W; Li Q; Li P; Yang L; Xia X; Yi X; Wan D Transl Oncol; 2021 Jan; 14(1):100945. PubMed ID: 33190041 [TBL] [Abstract][Full Text] [Related]
31. Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers. Briggs S; Tomlinson I J Pathol; 2013 Jun; 230(2):148-53. PubMed ID: 23447401 [TBL] [Abstract][Full Text] [Related]
32. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. Lee M; Eng G; Barbari SR; Deshpande V; Shcherbakova PV; Gala MK Clin Transl Gastroenterol; 2020 Mar; 11(3):e00149. PubMed ID: 32352724 [TBL] [Abstract][Full Text] [Related]
33. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Picard E; Verschoor CP; Ma GW; Pawelec G Front Immunol; 2020; 11():369. PubMed ID: 32210966 [TBL] [Abstract][Full Text] [Related]
34. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation. Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678 [TBL] [Abstract][Full Text] [Related]
35. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1 Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701 [TBL] [Abstract][Full Text] [Related]
37. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer. Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883 [TBL] [Abstract][Full Text] [Related]
38. Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas. Jung M; Lee JA; Yoo SY; Bae JM; Kang GH; Kim JH Mod Pathol; 2022 Dec; 35(12):2011-2022. PubMed ID: 35869301 [TBL] [Abstract][Full Text] [Related]
39. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080 [TBL] [Abstract][Full Text] [Related]
40. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]